Sequence Bio · Jun 2026
Sequence Bio announced a brand refresh reflecting its evolution toward in-house target identification and validation science and a broader discovery pipeline.
Discovering the true signals of disease to power life-changing drugs.
Company research
Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Overview
Sequence Bio is a Newfoundland and Labrador-based biotechnology research company focused on better, faster drug target discovery, leveraging population genetics and the Newfoundland founder effect to identify disease-relevant targets and support precision medicine/drug discovery.
Primary product
Drug target discovery and genomics research platform/services
Founded
2013
Headquarters
St. John’s, Newfoundland and Labrador, Canada
Team size
11-50
Industry
Biotechnology Research
Sub-industry
Genomics / drug target discovery / precision medicine
Offices
United States
Business model
B2B research collaboration
drug discovery partnerships
genomics data and analytics services
Funding
People & investors
Leadership
Lynn Healey
Chief Executive Officer
Tom Barber
Chief Scientific Officer
David Phillips
VP, Finance & Administration
Diane Power
Director Research Coordination
Cameron Nugent
Lead Bioinformatician
Timon Buys
Lead, Variant Scientist
Blair Davis
Director, Medical Partnerships
Founders
Chris Gardner
Co-founder / former COO / acting CEO (historical)
Tyler Wish
Founder and former CEO
Work & culture
Public-facing materials emphasize ethics, privacy, and returning benefits to the people whose data supports the research, but no detailed benefits package or formal culture statement was publicly confirmed in the sources reviewed.
Product & market
Pricing
Primarily partnership/collaboration-based; no public pricing found.
Differentiators
- —Uses Newfoundland founder effect / unique population genetics
- —Focus on genetic target discovery for hard-to-treat diseases
- —Combines population genomics with drug target discovery
- —Emphasis on ethics, privacy, and benefit return to community
Customers
LEO Pharma
Memorial University of Newfoundland and Labrador (research/data collaboration)
Competitors
deCODE genetics
23andMe (research/genetics platform adjacent)
Tempus
Helix
other genomics/drug-discovery data platforms
Scale & contact
Estimated monthly visits
89
Traffic estimate as of Jun 2026
Latest news
Sequence Bio · Dec 2024
Sequence Bio entered a research collaboration with Memorial University to study familial multiple sclerosis in Newfoundland and Labrador, aiming to identify novel drug targets.
Sequence Bio · Sep 2023
Sequence Bio named Lynn Healey CEO, promoting her from Chief Operating and Financial Officer.
PR Newswire · Apr 2022
Announced a discovery collaboration with LEO Pharma, supporting drug discovery efforts.
PR Newswire · Apr 2022
Sequence Bio announced a three-year discovery collaboration with LEO Pharma to use its platform for multi-omic analysis and dermatology target discovery.
Jobs and careers at Sequence Bio
11 jobs at Sequence Bio
GTM Associate
On-site
Revenue
New York City; New York, New York, USA
1mo ago
On-site
Full-time
AI Engineer - London
Remote
Engineering
London
4mo ago
Remote
Full-time
AI Engineer - NYC
Remote
Engineering
New York City
4mo ago
Remote
Full-time
Head of Finance / Expert in Residence [XIR]
On-site
CEO Office
New York City
4mo ago
On-site
Full-time
Senior Product Designer - London
On-site
Design
London
6mo ago
On-site
Full-time
Product Engineer - London
Remote
Engineering
London
6mo ago
Remote
Full-time
Senior Product Engineer (Frontend) - NYC
Remote
Engineering
New York City
7mo ago
Remote
Full-time
Revenue Associate - NYC
On-site
Revenue
New York City
11mo ago
On-site
Full-time
Senior Product Designer - NYC
On-site
Design
New York City
1y ago
On-site
Full-time
Senior Product Engineer (Backend) - London
Remote
Engineering
London
1y ago
Remote
Full-time
Senior Product Engineer (Backend) - NYC
Remote
Engineering
New York City
1y ago
Remote
Full-time